Atopic Dermatitis Clinical Trials 2023

Browse 87 Atopic Dermatitis Medical Studies Across 428 Cities

30 Phase 3 Trial · 2499 Atopic Dermatitis Clinics

Reviewed by Michael Gill, B. Sc.
10 Atopic Dermatitis Clinical Trials Near Me
Top Hospitals for Atopic Dermatitis Clinical Trials
Image of Dermatology Research Associates in California.
Dermatology Research Associates
Los Angeles
14Active Trials
29All Time Trials for Atopic Dermatitis
2005First Atopic Dermatitis Trial
Image of First OC Dermatology in California.
First OC Dermatology
Fountain Valley
11Active Trials
30All Time Trials for Atopic Dermatitis
2018First Atopic Dermatitis Trial
Image of Dawes Fretzin Clinical Research Group, LLC in Indiana.
Dawes Fretzin Clinical Research Group, LLC
Indianapolis
9Active Trials
26All Time Trials for Atopic Dermatitis
2005First Atopic Dermatitis Trial
Image of Clinical Science Institute in California.
Clinical Science Institute
Santa Monica
8Active Trials
24All Time Trials for Atopic Dermatitis
2016First Atopic Dermatitis Trial
Image of Progressive Clinical Research in Texas.
Progressive Clinical Research
San Antonio
7Active Trials
27All Time Trials for Atopic Dermatitis
2017First Atopic Dermatitis Trial
Top Cities for Atopic Dermatitis Clinical Trials
Image of Miami in Florida.
Miami
78Active Trials
Miami Dermatology and Laser ResearchTop Active Site
Image of Los Angeles in California.
Los Angeles
53Active Trials
Dermatology Research AssociatesTop Active Site
Atopic Dermatitis Clinical Trials by Phase of Trial
N/A Atopic Dermatitis Clinical Trials
4Active Atopic Dermatitis Clinical Trials
4Number of Unique Treatments
3Number of Active Locations
Atopic Dermatitis Clinical Trials by Age GroupMost Recent Atopic Dermatitis Clinical TrialsTop Treatments for Atopic Dermatitis Clinical Trials
Treatment Name
Active Atopic Dermatitis Clinical Trials
All Time Trials for Atopic Dermatitis
First Recorded Atopic Dermatitis Trial
Upadacitinib
5
10
2016
Dupilumab
5
38
2011
Nemolizumab
4
9
2017
Lebrikizumab
4
17
2015
Rocatinlimab
3
8
2022
Recently Completed Studies with FDA Approved Treatments for Atopic Dermatitis
Treatment
Year
Sponsor
EDP1815
2022
Evelo Biosciences, Inc.
dupilumab
2022
Regeneron Pharmaceuticals
Tralokinumab
2022
LEO Pharma
Ruxolitinib cream
2021
Incyte Corporation
LEO 152020 tablet
2021
LEO Pharma
GSK1070806
2021
GlaxoSmithKline
Tapinarof cream, 1%
2021
Dermavant Sciences, Inc.
ruxolitinib cream
2021
Incyte Corporation
tapinarof cream, 1%
2021
Dermavant Sciences GmbH
tapinarof cream, 1%
2021
Dermavant Sciences GmbH

What Are Atopic Dermatitis Clinical Trials?

Atopic dermatitis clinical trials are professional attempts to find better treatments for the chronic skin disease affecting more than 9.6 million children and an estimated 16.5 million adults in the US.

Described as the most common type of eczema by the National Eczema Association, atopic dermatitis is characterized by red, dry, itchy, inflamed, and irritated skin. It may become less severe with age, but it is a lifelong condition that doesn’t completely disappear. Patients tend to experience periods of flared symptoms and remission throughout life, requiring continuous care and treatment.

Why Is Atopic Dermatitis Being Studied Through Clinical Trials?

Atopic dermatitis is very common. According to the American Academy of Dermatology Associations, it affects about 1 in every 10 Americans. It’s also discomforting and often causes painful symptoms that disrupt the quality of one’s life. While the existing treatments of atopic dermatitis can help alleviate the symptoms and even make them go away for a while, the condition remains incurable to date. Clinical trials are attempts to find better treatments and, hopefully, a cure for the disease someday.

What Are The Types of Treatments Available For Atopic Dermatitis?

Finding the right treatment for atopic dermatitis requires a bit of a trial and error, as not every available treatment works for everyone. Bringing and keeping the condition under control also often requires using a combination of treatments from the following:

  • Emollients
  • Medicated creams or ointments
  • Antibiotics
  • Anti-inflammatory drugs
  • Biologics
  • Light therapy
  • Wet dressing
  • Counseling
  • Behavioral modifications
  • Lifestyle changes

What Are Some Recent Breakthrough Clinical Trials For Atopic Dermatitis?

2023: Researchers from Northwestern Medicine have recently published their findings of the international multi-site phase III trials in The Lancet. First of its kind, the study investigated the efficacy of Dupilumab – a biologic drug – to treat moderate to severe atopic dermatitis in infants and young children aged six months to five years. The study found the drug to be highly effective in treating the symptoms.

2021: A research study published in The Journal of Allergy and Clinical Immunology: In Practice found JAK inhibitor drugs to be effective in treating moderate-to-severe atopic dermatitis. JAK (Janus Kinase) inhibitors are oral medications that help reduce skin inflammation by blocking certain immune signals involved in it.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Atopic Dermatitis Clinical Trial Research?

Atopic Dermatitis Research Network: An association of academic medical centers conducts research studies and clinical trials on atopic dermatitis to better understand the skin condition and associated infections and the immune response of atopic dermatitis patients to create more targeted therapies and treatments.

National Eczema Association: NEA is a non-profit organization dedicated to improving knowledge and treatments available for different types of eczema. The organization funds and conducts studies and trials to advance eczema research.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: August 27th, 2023

References1 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6. doi: 10.1111/j.1365-2230.1994.tb01167.x. https://pubmed.ncbi.nlm.nih.gov/80333782 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6. https://pubmed.ncbi.nlm.nih.gov/80333783 Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001 Feb;10(1):11-8. https://pubmed.ncbi.nlm.nih.gov/111685754 Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001 Feb;10(1):11-8. doi: 10.1034/j.1600-0625.2001.100102.x. https://pubmed.ncbi.nlm.nih.gov/111685755 Bieber T. Atopic dermatitis. N Engl J Med. 2008 Apr 3;358(14):1483-94. doi: 10.1056/NEJMra074081. https://pubmed.ncbi.nlm.nih.gov/183855006 Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005 May-Jun;22(3):192-9. Review. https://pubmed.ncbi.nlm.nih.gov/159165637 Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. https://pubmed.ncbi.nlm.nih.gov/344066198 Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, Dubois AE, Beyer K, Eigenmann PA, Spergel JM, Werfel T, Chinchilli VM. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol. 2012 Dec;130(6):1260-74. doi: 10.1016/j.jaci.2012.10.017. No abstract available. https://pubmed.ncbi.nlm.nih.gov/231955259 Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. Erratum in: Am J Clin Dermatol. 2021 Nov;22(6):905. https://pubmed.ncbi.nlm.nih.gov/3440661910 Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. Erratum in: Am J Clin Dermatol. 2021 Oct 13;:. https://pubmed.ncbi.nlm.nih.gov/34406619